1IA
CORT icon

1834 Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

1834 Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-141
Closed -$2K – 427
2020
Q2 		$2K Buy
+141
New +$1.98K ﹤0.01% 420

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1834 Investment Advisors's CORT Position: Q3 2020 in Review

1834 Investment Advisors sold out of Corcept Therapeutics (CORT) in Q3 2020, closing a stake of 141 shares — an estimated $2K sold.

1834 Investment Advisors first reported a position in CORT in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 223 funds tracked by Wall St. Rank hold CORT as of Q3 2020.

  • 1834 Investment Advisors reported no remaining Corcept Therapeutics position as of Q3 2020 after selling out during the quarter.
  • 1834 Investment Advisors sold 141 Corcept Therapeutics shares in Q3 2020, an estimated $2K.
  • 1834 Investment Advisors first reported a position in Corcept Therapeutics in Q2 2020 and held it in 1 quarter.
  • 1834 Investment Advisors's Corcept Therapeutics position peaked at $2K in Q2 2020.
  • 223 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2020.

Based on 1834 Investment Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.